|
|
Post by peppy on Feb 5, 2016 7:04:42 GMT -5
The way marijuana becomes medicine is the THC is taken out. Thus making it proprietary.
I think it would be grand if technosphere was used for the seizures some people suffer.
Interesting to find out if these compounds could help with spasms,muscle spasms.
I think one of the effects of marijuana is it slows down the synapse.... 
en.wikipedia.org/wiki/Synapse
|
|
|
|
Post by patten1962 on Feb 5, 2016 7:12:39 GMT -5
The way marijuana becomes medicine is the THC is taken out. Thus making it proprietary.
I think it would be grand if technosphere was used for the seizures some people suffer.
Interesting to find out if these compounds could help with spasms,muscle spasms.
I think one of the effects of marijuana is it slows down the synapse....
Matt said in the conference call that receptor Life Sciences is a well established older company that is changing its name. He cannot lie about this so I take it is the truth! I think this is wonderful news for investors regardless of who the company really is. The fact that we are moving forward with a well established company and a great delivery system for insulin and a drug that really works is really VERY positive! |
|
|
|
Post by lorcan458 on Feb 5, 2016 8:22:31 GMT -5
Ok kids- the last 2 pages (of this 9 page thread) are sounding fun. So here's the deal: Google- of course that would be awesome, just hard to swallow without Kool-aid, but it would be my fav. Omeros- much more normal thinking that could make sense. Boring sense in comparison to GOOGLE! OK, let's say RLS isn't Google. The one overall question that remains is this: Why did Google choose Sanofi? 1. Given that Google Life Sciences was looking to innovate diabetes treament with new technology at the time they signed with Sanofi, why Sanofi? 2. Is there any other truly innovative diabetes medicine other than the one the Sanofi had 65% of at the time Google partnered with them? 3. Google's own innovation is a glucose monitoring contact lens. What fits better with Afrezza than a realtime glucose monitor (as shown by the Dexcom CEO's comments and the ever-increasing number of Twitter posts with glucose monitoring graphs)? Even if Google isn't RLS, I don't think it's pie in the sky that what attracted Google to Sanofi was Afrezza. |
|
|
|
Post by mnholdem on Feb 5, 2016 8:33:26 GMT -5
Have you considered the possibility that Google may have interest in Sanofi more for its 120-countries global sales presence than for any of its products?
|
|
akil
Newbie
Posts: 21 
|
Post by akil on Feb 5, 2016 8:35:41 GMT -5
Secrecy? Apple? Would be clear why they were secretive if it were them. Of course, that would be very foolish of Apple. Can't be them.
|
|
|
|
Post by dictatorsaurus on Feb 5, 2016 8:37:30 GMT -5
Ok kids- the last 2 pages (of this 9 page thread) are sounding fun. So here's the deal: Google- of course that would be awesome, just hard to swallow without Kool-aid, but it would be my fav. Omeros- much more normal thinking that could make sense. Boring sense in comparison to GOOGLE! OK, let's say RLS isn't Google. The one overall question that remains is this: Why did Google choose Sanofi? 1. Given that Google Life Sciences was looking to innovate diabetes treament with new technology at the time they signed with Sanofi, why Sanofi? 2. Is there any other truly innovative diabetes medicine other than the one the Sanofi had 65% of at the time Google partnered with them? 3. Google's own innovation is a glucose monitoring contact lens. What fits better with Afrezza than a realtime glucose monitor (as shown by the Dexcom CEO's comments and the ever-increasing number of Twitter posts with glucose monitoring graphs)? Even if Google isn't RLS, I don't think it's pie in the sky that what attracted Google to Sanofi was Afrezza. There was no mention of Afrezza whatsoever when Google chose Sanofi. Saw mention of "inhaled insulin" but no mention of the drug name. |
|
akil
Newbie
Posts: 21
|
Post by akil on Feb 5, 2016 8:39:12 GMT -5
I hope I made at least some of you laugh at my apple comment  Trying to make the world a better place! |
|
|
|
Post by lorcan458 on Feb 5, 2016 9:33:18 GMT -5
Have you considered the possibility that Google may have interest in Sanofi more for its 120-countries global sales presence than for any of its products?
I have to admit, no. And I freely admit, I could be absolutely wrong, but if I am, it's because Afrezza truly SHOULD be what any innovative diabetes treatment should have front and center along with realtime glucose monitoring and data collection and analysis for dosage optimization.
How does Google make their money...what's their core business? Online advertising, sales and marketing. If Google plans to innovate in the healthcare space, I'd think they'd want to change how medication is "sold" to doctors considering the trend of making a human salesforce getting face time and giving perks to doctors is well on the way out the door.
With a company like Google, I'd expect extensive online technology and realtime communication, monitoring and data collection and analysis to be their top priority, not a global salesforce of hucksters in suits trying to bribe doctors.
|
|
|
|
Post by cathode on Feb 5, 2016 10:24:11 GMT -5
Ok kids- the last 2 pages (of this 9 page thread) are sounding fun. So here's the deal: Google- of course that would be awesome, just hard to swallow without Kool-aid, but it would be my fav. Omeros- much more normal thinking that could make sense. Boring sense in comparison to GOOGLE! 1. Given that Google Life Sciences was looking to innovate diabetes treament with new technology at the time they signed with Sanofi, why Sanofi? 2. Is there any other truly innovative diabetes medicine other than the one the Sanofi had 65% of at the time Google partnered with them? 3. Google's own innovation is a glucose monitoring contact lens. What fits better with Afrezza than a realtime glucose monitor (as shown by the Dexcom CEO's comments and the ever-increasing number of Twitter posts with glucose monitoring graphs)? Even if Google isn't RLS, I don't think it's pie in the sky that what attracted Google to Sanofi was Afrezza. There is such a big probability that the RLS AGREEMENT HAS NOTHING TO DO WITH DIABETES! What evidence do you have that it does? There is loads of other evidence that it does not. Strongest among the evidence is the press release that mentions the target applications by name. Regarding the Verily-Sanofi agreement -- I think, like you, that Verily is interested in Afrezza, or at least that is why they teamed with Sanofi to begin. I don't know how that collaboration will be progressing following the Afrezza termination. I will be closely following the advances in BG monitoring technology that come from the Verily team up with DXCM and Novartis. |
|
|
|
Post by esstan2001 on Feb 5, 2016 10:38:33 GMT -5
..... Regarding the Verily-Sanofi agreement -- I think, like you, that Verily is interested in Afrezza, or at least that is why they teamed with Sanofi to begin. I don't know how that collaboration will be progressing following the Afrezza termination. I will be closely following the advances in BG monitoring technology that come from the Verily team up with DXCM and Novartis. It is very possible that you are correct, and how many times (often) have agreements that were entered into, yielded no forward progress, and subsequently been dissolved. Google may end it's association with SNY at some point if this is the case. |
|
|
|
Post by mnholdem on Feb 5, 2016 12:03:48 GMT -5
Another company of interest is Algomedix, Inc. of Mill Creek, WA (Link: www.algomedix.com/ )
"Algomedix is an emerging biopharmaceutical company focused on developing novel therapeutics for the treatment of chronic pain and inflammation."
MannKind's PR about partnering with Receptor Life Sciences mentions therapeutic areas of chronic pain, neurological diseases and inflammatory disorders. Algomedix is developing treatments for at least two of these areas.
Also, Jeffrey Herz, the President and CEO since 2010, was previous the Director of Discovery Research at Omeros Corporation, which was presented earlier in this thread.
Not much information is available on Algomedix other than what appears on their website, which doesn't contain much itself.
About Us
Algomedix is an emerging biopharmaceutical company focused on developing novel therapeutics for the treatment of chronic pain and inflammation. More than 100 million Americans suffer from chronic pain. Existing therapeutics for chronic pain based upon opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are inadequate in addressing patient and physician needs, as well as a regulatory issue for the FDA. Use of these existing medicines presents significant safety, tolerability, abuse and addiction concerns that limit use. A major unmet medical need is an effective therapeutic for chronic pain that is devoid of both addictive potential and abuse liability. Algomedix has discovered and is developing a novel non-opiod drug that solves these problems. The estimated market for this potential first-in-class drug in the primary indication is estimated > $1 billion.
Our Approach
Our approach to discovery and development of a first-in-class analgesic is based upon a novel approach to pain relief: blocking pain at its source in the peripheral nervous system. In addition, the new drug acts as an analgesic by a defined mechanism of action. The target for the Algomedix drug is located on the endings of sensory nerves that transmit the sensations of pain and hyperalgesia in response to inflammation and injury. Our rational drug discovery approach has resulted in the identification of numerous novel agonists and antagonists. The Algomedix lead compound is protectable from an independent IP position, characterized by drug-like properties and acts by a defined mechanism of action. The next-generation therapeutic we are developing has many factors correlated with commercial success and will be highly differentiated from existing analgesics at launch.
---
If MannKind's new partner originated from the Seattle area, Algomedix seems like a possible candidate for the mystery question: "Who is Receptor Life Sciences?"
Of course, Receptor may be throwing everybody a curve ball by registering the new company name in Seattle, WA. For all we know, Receptor could be a rename of a company from the Boston-Connecticut area known for its many biotech/drug development companies.   
|
|
|
|
Post by babaoriley on Feb 5, 2016 12:48:05 GMT -5
The way marijuana becomes medicine is the THC is taken out. Thus making it proprietary.
I think it would be grand if technosphere was used for the seizures some people suffer.
Interesting to find out if these compounds could help with spasms,muscle spasms.
I think one of the effects of marijuana is it slows down the synapse....
en.wikipedia.org/wiki/Synapse
Oh, wow. Far out, Peppy. |
|
|
|
Post by sccrbrg on Feb 5, 2016 12:59:11 GMT -5
Another company of interest is Algomedix, Inc. of Mill Creek, WA (Link: www.algomedix.com/ )
"Algomedix is an emerging biopharmaceutical company focused on developing novel therapeutics for the treatment of chronic pain and inflammation."
MannKind's PR about partnering with Receptor Life Sciences mentions therapeutic areas of chronic pain, neurological diseases and inflammatory disorders. Algomedix is developing treatments for at least two of these areas.
Also, Jeffrey Herz, the President and CEO since 2010, was previous the Director of Discovery Research at Omeros Corporation, which was presented earlier in this thread.
Not much information is available on Algomedix other than what appears on their website, which doesn't contain much itself.
About Us
Algomedix is an emerging biopharmaceutical company focused on developing novel therapeutics for the treatment of chronic pain and inflammation. More than 100 million Americans suffer from chronic pain. Existing therapeutics for chronic pain based upon opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are inadequate in addressing patient and physician needs, as well as a regulatory issue for the FDA. Use of these existing medicines presents significant safety, tolerability, abuse and addiction concerns that limit use. A major unmet medical need is an effective therapeutic for chronic pain that is devoid of both addictive potential and abuse liability. Algomedix has discovered and is developing a novel non-opiod drug that solves these problems. The estimated market for this potential first-in-class drug in the primary indication is estimated > $1 billion.
Our Approach
Our approach to discovery and development of a first-in-class analgesic is based upon a novel approach to pain relief: blocking pain at its source in the peripheral nervous system. In addition, the new drug acts as an analgesic by a defined mechanism of action. The target for the Algomedix drug is located on the endings of sensory nerves that transmit the sensations of pain and hyperalgesia in response to inflammation and injury. Our rational drug discovery approach has resulted in the identification of numerous novel agonists and antagonists. The Algomedix lead compound is protectable from an independent IP position, characterized by drug-like properties and acts by a defined mechanism of action. The next-generation therapeutic we are developing has many factors correlated with commercial success and will be highly differentiated from existing analgesics at launch.
---
If MannKind's new partner originated from the Seattle area, Algomedix seems like a possible candidate for the mystery question: "Who is Receptor Life Sciences?"
Of course, Receptor may be throwing everybody a curve ball by registering the new company name in Seattle, WA. For all we know, Receptor could be a rename of a company from the Boston-Connecticut area known for its many biotech/drug development companies.
Myself and another poster brought this up earlier in the discussion. Jeffrey Herz is also associated with an entity called "Applied Receptor Sciences". I still think this is the closest guess thus far as it seems to fit all of the parameters. |
|
|
|
Post by mnholdem on Feb 5, 2016 13:03:43 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 5, 2016 13:03:55 GMT -5
Another company of interest is Algomedix, Inc. of Mill Creek, WA (Link: www.algomedix.com/ )
"Algomedix is an emerging biopharmaceutical company focused on developing novel therapeutics for the treatment of chronic pain and inflammation."
MannKind's PR about partnering with Receptor Life Sciences mentions therapeutic areas of chronic pain, neurological diseases and inflammatory disorders. Algomedix is developing treatments for at least two of these areas.
Also, Jeffrey Herz, the President and CEO since 2010, was previous the Director of Discovery Research at Omeros Corporation, which was presented earlier in this thread.
Not much information is available on Algomedix other than what appears on their website, which doesn't contain much itself.
About Us
Algomedix is an emerging biopharmaceutical company focused on developing novel therapeutics for the treatment of chronic pain and inflammation. More than 100 million Americans suffer from chronic pain. Existing therapeutics for chronic pain based upon opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are inadequate in addressing patient and physician needs, as well as a regulatory issue for the FDA. Use of these existing medicines presents significant safety, tolerability, abuse and addiction concerns that limit use. A major unmet medical need is an effective therapeutic for chronic pain that is devoid of both addictive potential and abuse liability. Algomedix has discovered and is developing a novel non-opiod drug that solves these problems. The estimated market for this potential first-in-class drug in the primary indication is estimated > $1 billion.
Our Approach
Our approach to discovery and development of a first-in-class analgesic is based upon a novel approach to pain relief: blocking pain at its source in the peripheral nervous system. In addition, the new drug acts as an analgesic by a defined mechanism of action. The target for the Algomedix drug is located on the endings of sensory nerves that transmit the sensations of pain and hyperalgesia in response to inflammation and injury. Our rational drug discovery approach has resulted in the identification of numerous novel agonists and antagonists. The Algomedix lead compound is protectable from an independent IP position, characterized by drug-like properties and acts by a defined mechanism of action. The next-generation therapeutic we are developing has many factors correlated with commercial success and will be highly differentiated from existing analgesics at launch.
---
If MannKind's new partner originated from the Seattle area, Algomedix seems like a possible candidate for the mystery question: "Who is Receptor Life Sciences?"
Of course, Receptor may be throwing everybody a curve ball by registering the new company name in Seattle, WA. For all we know, Receptor could be a rename of a company from the Boston-Connecticut area known for its many biotech/drug development companies.
Myself and another poster brought this up earlier in the discussion. Jeffrey Herz is also associated with an entity called "Applied Receptor Sciences". I still think this is the closest guess thus far as it seems to fit all of the parameters. and his patents www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Jeffrey+M.+Herz%22&gws_rd=ssl |
|
Trying to make the world a better place!
